Home Ingredients Hyaluronic Acid
Hair, Skin & NailsJoint Health

Hyaluronic Acid

Evidence Level
Moderate
7 Clinical Trials
4 Documented Benefits
3/5 Evidence Score

Hyaluronic acid is a naturally occurring substance in the body, primarily found in connective tissues, skin, and eyes, known for its ability to retain moisture and support tissue hydration. As a dietary supplement, it is often taken to promote skin elasticity, reduce wrinkles, and support joint health by lubricating joints and reducing inflammation. Research suggests it may improve skin appearance and alleviate joint pain, though results vary and more studies are needed to confirm long-term benefits.

Studied Dose 80–200 mg/day oral for joint and skin benefits; skin: 120–240 mg/day; low molecular weight HA (50–300 kDa) best for oral bioavailability; topical: 0.1–2% concentration
Active Compound Sodium Hyaluronate (high molecular weight)

Benefits

Skin Health

Oral and topical HA improves skin hydration, elasticity, and reduces wrinkles. Studies show significant improvements in stratum corneum water content, transepidermal water loss, and wrinkle volume after 8–12 weeks of use (120–150 mg/day oral or topical application, p < 0.05). It enhances skin smoothness and plumpness, particularly in aging or dry skin.

Supported by Trial 2

Joint Health

Intra-articular HA injections reduce pain and improve function in osteoarthritis (e.g., knee, shoulder). A trial showed pain reduction (SMD: -0.39, p < 0.001) with high molecular weight HA, though effects vary by formulation and placebo response.

Supported by Trial 5, Trial 1

Wound Healing

HA-containing creams accelerate healing and reduce pain in chronic leg ulcers (p < 0.05), with no serious adverse effects.

Supported by Trial 6

Other Potential Benefits

Limited evidence suggests HA may improve sleep quality (via dietary intake studies) and support eye health (e.g., dry eye relief via HA eye drops). Data on oral HA for other conditions like muscle recovery or systemic inflammation are promising but inconclusive.

Supported by Trial 2, Trial 1

Mechanism of action

1

Hydration

HA, a glycosaminoglycan, binds water molecules (up to 1,000 times its weight), increasing stratum corneum water content and reducing transepidermal water loss. This enhances skin hydration and barrier function.

2

Structural Support

HA interacts with collagen and elastin in the dermis, improving skin elasticity and firmness. Low molecular weight HA (<300 kDa) penetrates deeper, stimulating fibroblast activity and extracellular matrix production.

3

Anti-Aging

HA reduces oxidative stress and inflammation in skin cells, mitigating wrinkle formation and photoaging by modulating cytokine activity and protecting against UV damage.

4

Lubrication and Shock Absorption

HA restores viscoelasticity in synovial fluid, reducing friction in joints and cushioning cartilage in osteoarthritis. High molecular weight HA (>1,500 kDa) is most effective.

5

Anti-Inflammatory Effects

HA binds to CD44 receptors on chondrocytes, inhibiting pro-inflammatory cytokines (e.g., IL-1β, TNF-α) and matrix metalloproteinases, which reduces cartilage degradation.

6

Pain Reduction

HA modulates nociceptive signaling, potentially by coating pain-sensitive joint structures or altering synovial fluid dynamics.

7

Moisture Retention

HA creates a hydrated environment, promoting cell migration and tissue repair in chronic wounds (e.g., venous ulcers).

8

Angiogenesis and Fibroblast Activity

HA stimulates angiogenesis and fibroblast proliferation via CD44 and RHAMM receptor interactions, accelerating granulation tissue formation and re-epithelialization.

9

Anti-Inflammatory

HA reduces local inflammation by scavenging free radicals and downregulating inflammatory mediators.

Clinical trials

1
Intra-Articular Hyaluronic Acid for OA — Real-World Review

Review of real-world setting trials and surveys examining intra-articular hyaluronic acid (IA-HA) injections for osteoarthritis. (— or 2016 OARSI guideline-related reviews)

Pooled across observational and trial data.

IA-HA produces modest pain reduction in real-world OA management; effect sizes typically smaller than published clinical trials suggest. Evidence quality varied. Note: IA-HA injections (Synvisc®, Orthovisc®, Euflexxa®) are medical devices administered by clinicians — fundamentally different from oral HA supplements. Insurance coverage varies by jurisdiction; US Medicare coverage rules have tightened. Modern OARSI guidelines have downgraded IA-HA recommendations.

2
Hyaluronic Acid Therapy for OA — Comprehensive Review

Review of 44 prospective clinical trials examining intra-articular and oral HA for knee, hip, and ankle OA. (2018)

Pooled across 44 trials.

IA-HA: modest pain and function benefits, particularly in early-moderate OA. Oral HA: smaller effect sizes; evidence is encouraging but less robust than for IA-HA. Most oral HA trials use 80-200 mg/day for 8-12 weeks. Mechanism for oral HA is debated — high-MW HA is poorly absorbed; low-MW HA may have systemic effects but the magnitude is unclear.

3
Oral Sodium Hyaluronate for Knee OA — Italian Pilot Clinical Trial

Pilot clinical trial in 60 patients with symptomatic knee OA comparing oral sodium hyaluronate (FS-HA®) vs placebo for 8 weeks. (2020 Italian trial)

60 knee OA patients. 8-week intervention.

Oral HA modestly reduced WOMAC pain and stiffness vs placebo. Note: small pilot trial; effects modest. Oral HA evidence base is much weaker than IA-HA — buyers should not assume oral HA provides comparable benefit to injected HA.

4
IA-Hyaluronan for Knee OA — Low Risk-of-Bias Evidence Synthesis

Pooled analysis of clinical trials with low risk of bias focusing on IA-HA for knee OA. Inclusion limited to trials with at least 100 patients per arm. (2015)

Pooled across rigorous IA-HA trials.

When restricted to low RISK-OF-BIAS trials, IA-HA effects on knee OA pain were smaller than earlier pooled analyses suggested. Effect size barely clinically meaningful. Important methodological context: industry funding and trial bias historically inflated IA-HA effect estimates.

5
Intermediate vs High Molecular Weight IA-HA — Direct Comparison Clinical Trial

Randomized, double-blind, controlled trial in 426 patients with symptomatic knee OA comparing intermediate molecular weight HA (GO-ON, 800-1,500 kDa) vs high molecular weight HA. (2012, Ann Rheum Dis)

426 knee OA patients.

No statistically significant differences between intermediate and high molecular weight IA-HA preparations on pain or function outcomes. The 'higher MW = better' marketing claim is not strongly supported by direct comparison data.

6
Viscosupplementation for Knee OA — 2022 Comprehensive Evidence Synthesis

Pooled analysis of clinical trials from 1970-2021 comparing IA-HA to placebo for knee OA. Outcomes: pain, function, adverse events. (BMJ)

Comprehensive clinical trial pooling, 1970-2021.

IA-HA showed only small, clinically irrelevant pain reduction vs placebo when restricted to higher-quality trials. Risk of serious adverse events (acute reactions, septic arthritis) was elevated. Authors concluded IA-HA should not be routinely used. This reflects the current direction in OA guidelines (OARSI 2019: not recommended; AAOS: limited recommendation).

7
Glucosamine + Sodium Hyaluronate for Osteoporosis-Related Vertebral Pain

Trial evaluating glucosamine combined with sodium hyaluronate vs glucosamine alone for vertebral compression fracture pain in osteoporotic patients.

Osteoporotic patients with vertebral compression fractures.

Combination outperformed glucosamine alone for pain measures. Note: this is a niche application; most osteoporosis-related pain is managed with bisphosphonates, calcium, vitamin D, vertebroplasty, and analgesics rather than HA combinations.

Side effects and drug interactions

Common Potential side effects

Mild gastrointestinal issues: Nausea, bloating, diarrhea) reported infrequently.
Allergic reactions: Rare allergic reactions (e.g., rash, itching) in individuals with sensitivities, particularly to poultry-derived HA.

Important Drug interactions

Anticoagulants (warfarin, heparin) — hyaluronic acid is structurally related to heparin; intra-articular injection forms carry theoretical bleeding risk; oral supplementation at standard doses shows no established interaction
NSAIDs and corticosteroids — often co-administered with HA injections for joint pain; oral HA is generally complementary to anti-inflammatory medications
No clinically established drug interactions for oral hyaluronic acid supplementation at standard doses (80–200 mg/day)

More Hair, Skin & Nails Ingredients

Cardiovascular
Niacin
Niacin (vitamin B3) is an essential water-soluble vitamin central to energy metabolism, DN…
Cardiovascular
Omega-3 Fatty Acids
Omega-3 fatty acids, primarily eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), an…
Immune Support
Vitamin C
Vitamin C (L-ascorbic acid) is a water-soluble essential nutrient that humans cannot synth…
Immune Support
Zinc
Zinc, an essential trace mineral, is commonly supplemented in forms like zinc gluconate, a…

Explore Other Ingredients

Muscle & Recovery
Bromelain
Bromelain is a group of protein-digesting enzymes extracted from pineapple stems, used in…
Bone Health
Collagen
Collagen is the most abundant structural protein in the human body — making up roughly 30%…
Cognitive
Suntheanine®
Suntheanine® is a patented, 100% pure L-isomer theanine produced via an enzymatic process…

Related articles from our blog

📝 Article
Hyaluronic Acid as a Supplement: Benefits, Clinical Trials, and Uses
Hyaluronic acid (HA) is a naturally occurring substance in the human body known for its remarkable ability to retain moi…
July 07, 2025
📝 Article
Top 5 Best Hair, Skin and Nails Supplements of 2026
Beauty from Within is Important In 2026, the pursuit of healthy hair, radiant skin, and strong nails is more popular tha…
July 12, 2025
📝 Article
✨ Collagen: The Key to Youthful Skin, Strong Joints, and Healthy Hair
Collagen is one of the most popular supplements in the health and wellness world — and for good reason. As the most abun…
July 04, 2025

Frequently asked questions about Hyaluronic Acid

What is hyaluronic acid used for?

Hyaluronic acid is a moisture-binding molecule naturally found in skin and joints. It is used orally and topically for skin hydration and a plump, smooth look, and is studied for joint comfort and lubrication.

Does oral hyaluronic acid work for skin?

Some studies suggest oral hyaluronic acid may support skin hydration and elasticity over weeks of use, as it provides building blocks and may signal the body to make more. Topical HA hydrates the skin surface directly.

How much hyaluronic acid should I take?

Oral skin studies often use about 120 to 240 mg per day; joint studies vary. Follow product labeling and give skin or joint goals 8 to 12 weeks. It is often paired with collagen and vitamin C.

Is hyaluronic acid safe?

Hyaluronic acid is generally very safe and well tolerated, both orally and topically, since it is a substance the body already makes. As with any supplement, those who are pregnant or on medication should check with a doctor.

What is Hyaluronic Acid?

Hyaluronic acid is a naturally occurring substance in the body, primarily found in connective tissues, skin, and eyes, known for its ability to retain moisture and support tissue hydration.

What is the recommended dosage of Hyaluronic Acid?

The clinically studied dose is 80–200 mg/day oral for joint and skin benefits; skin: 120–240 mg/day; low molecular weight HA (50–300 kDa) best for oral bioavailability; topical: 0.1–2% concentration Always follow the product label and check with a healthcare provider for personal advice.

Is Hyaluronic Acid safe, and does it have side effects?

For most healthy adults, Hyaluronic Acid is well tolerated at studied doses. Reported effects can include: Mild gastrointestinal issues: Nausea, bloating, diarrhea) reported infrequently. Allergic reactions: Rare allergic reactions (e.g., rash, itching) in individuals with sensitivities, particularly to poultry-derived HA. It may also interact with some medications. Hyaluronic Acid is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Hyaluronic Acid interact with any medications?

Possible interactions include: Anticoagulants (warfarin, heparin) — hyaluronic acid is structurally related to heparin; intra-articular injection forms carry theoretical bleeding risk; oral supplementation at standard doses shows no established interaction NSAIDs and corticosteroids — often co-administered wit… If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Hyaluronic Acid?

NutraSmarts rates the evidence for Hyaluronic Acid as Moderate (3 out of 5). It is backed by 7 clinical trials and 8 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(8 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Kalman DS, Heimer M, Valdeon A, Schwartz H, Sheldon E. Effect of a natural extract of chicken combs with a high content of hyaluronic acid (Hyal-Joint) on pain relief and quality of life in subjects with knee osteoarthritis: a pilot randomized double-blind placebo-controlled trial. Nutr J. 2008;7:3. doi: 10.1186/1475-2891-7-3.PubMedUsed to support: Pilot RCT (n=20) of Hyal-Joint oral HA 80 mg/day in knee osteoarthritis: HA group showed significantly improved knee pain and quality of life vs placebo (p<0.05). Small but representative trial supporting the page's oral HA framing for joint comfort — effect size modest, evidence base much weaker than IA-HA.
  2. Berenbaum F, Grifka J, Cazzaniga S, D'Amato M, Giacovelli G, Chevalier X, Rannou F, Rovati LC, Maheu E. A randomised, double-blind, controlled trial comparing two intra-articular hyaluronic acid preparations differing by their molecular weight in symptomatic knee osteoarthritis. Ann Rheum Dis. 2012;71(9):1454-60. doi: 10.1136/annrheumdis-2011-200972.PubMedUsed to support: Randomised non-inferiority trial in symptomatic knee OA comparing intermediate MW (GO-ON, 800-1500 kDa) vs high MW (Hyalgan, 500-730 kDa) IA-HA: no statistically significant differences in WOMAC pain at 6 months. Directly matches trial card #5 — backs the page's claim that 'higher MW = better' marketing isn't supported by direct comparison data.
  3. Tashiro T, Seino S, Sato T, Matsuoka R, Masuda Y, Fukui N. Oral administration of polymer hyaluronic acid alleviates symptoms of knee osteoarthritis: a double-blind, placebo-controlled study over a 12-month period. ScientificWorldJournal. 2012;2012:167928. doi: 10.1100/2012/167928.PubMedUsed to support: 12-month double-blind placebo-controlled RCT in 60 adults with Kellgren-Lawrence grade 2-3 knee OA: oral polymer HA 200 mg/day + quadriceps strengthening modestly improved Japanese Knee OA Measure (JKOM) scores vs placebo + exercise. Directly matches trial card #3 — small pilot, modest effects; oral HA evidence remains weaker than IA-HA.
  4. Rutjes AW, Jüni P, da Costa BR, Trelle S, Nüesch E, Reichenbach S. Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis. Ann Intern Med. 2012;157(3):180-91. doi: 10.7326/0003-4819-157-3-201208070-00473.PubMedUsed to support: Systematic review + meta-analysis of 71 IA-HA trials (n=9,617): all-trials pooled effect size -0.37 for pain, but in 18 large blinded-outcome trials (n=5,094) the effect was clinically irrelevant (-0.11). Increased risk of serious local adverse events. Authors recommend discouraging IA-HA. Directly matches trial card #4 — the low-risk-of-bias synthesis.
  5. Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med. 2015;162(1):46-54. doi: 10.7326/M14-1231.PubMedUsed to support: Network meta-analysis comparing all knee OA pharmacologic interventions including IA-HA against each other and against IA-placebo: IA-HA showed modest improvement vs oral placebo but smaller benefit than NSAIDs or IA-corticosteroids. Backs the page's trial card #1 framing of IA-HA delivering 'modest pain reduction' in real-world comparative effectiveness.
  6. Oe M, Tashiro T, Yoshida H, Nishiyama H, Masuda Y, Maruyama K, Koikeda T, Maruya R, Fukui N. Oral hyaluronan relieves knee pain: a review. Nutr J. 2016;15:11. doi: 10.1186/s12937-016-0128-2.PubMedUsed to support: Review of oral HA clinical evidence covering 13 trials. Oral HA at 80-200 mg/day for 8-12 weeks produced symptomatic improvement in knee OA. Authors discuss the absorption-mechanism debate (high-MW HA poorly absorbed; low-MW HA reaching tissues via different routes). Directly matches trial card #2's framing of oral HA evidence as 'encouraging but less robust than IA-HA'.
  7. Oe M, Sakai S, Yoshida H, Okado N, Kaneda H, Masuda Y, Urushibata O. Oral hyaluronan relieves wrinkles: a double-blinded, placebo-controlled study over a 12-week period. Clin Cosmet Investig Dermatol. 2017;10:267-273. doi: 10.2147/CCID.S141845.PubMedUsed to support: 12-week double-blind placebo-controlled RCT in 60 Japanese adults aged 22-59 with crow's feet wrinkles: oral HA 120 mg/day (at either 2 kDa or 300 kDa MW) significantly improved skin hydration and reduced wrinkle volume vs placebo, with smaller MW HA showing slight advantage. Backs the page's benefit #1 (skin) framing of oral HA 120-240 mg/day for 8-12 weeks.
  8. Pereira TV, Jüni P, Saadat P, Xing D, Yao L, Bobos P, Agarwal A, Hincapié CA, da Costa BR. Viscosupplementation for knee osteoarthritis: systematic review and meta-analysis. BMJ. 2022;378:e069722. doi: 10.1136/bmj-2022-069722.PubMedUsed to support: Modern systematic review of 169 IA-HA trials. In 15 large placebo-controlled trials (n=6,462), IA-HA showed only small, clinically irrelevant pain reduction and increased serious adverse events (3.7% vs 2.5%; RR 1.49, 95% CI 1.12-1.98). Authors conclude IA-HA should not be routinely used. Directly matches trial card #6 — the current direction in OA guidelines.